-
Approved at 2024
Annual General Meeting".
Morphosys de.
Retrieved 2024-08-28. "tafasitamab".
MorphoSys. "
MorphoSys Signs Regional License Agreement for Antibody...
- are
invalid because of obviousness." The
German biotechnology company MorphoSys generates human antibodies using its
phage display-based 'HuCal' (Human...
- cancer-centric
MorphoSys for $2.9 bln". Reuters. 5
February 2024.
Retrieved 5
February 2024. "German
regulators approve Novartis deal to buy
drugmaker Morphosys"....
- for the
global development and
commercialization of
tafasitamab with
MorphoSys. On
March 3, 2020, the
agreement received antitrust clearance and thus...
- More Than $10 Billion". WSJ.
Retrieved 2023-12-01. AG,
MorphoSys (26
January 2016). "
MorphoSys Announces Clinical Milestone for
Start of Bayer's Phase...
- variation. In
January 2013, Bio-Rad
purchased AbD Serotec, a
division of
MorphoSys AG. This
added Serotec’s more than 15,000 antibodies, kits, and accessories...
-
human antibody which has been
developed by the
biotechnology company MorphoSys. It can also be
referred to as
HuCAL antibody,
HuCAL standing for Human...
- (since 2017)
Lonza Group,
Member of the
Board of
Directors (2012-2013)
MorphoSys,
Member of the
Supervisory Board (2001-2004)
Temasek Holdings, Member...
-
Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2). "Ianalumab -
MorphoSys/Novartis". AdisInsight.
Springer Nature Switzerland AG. van den Hoogen...
- biotech-companies, like ADVA
Optical Networking, GPC Biotech,
MediGene and
MorphoSys. In addition, the Max
Planck Institute of
Biochemistry and the Max Planck...
